

Connecticut Department of Consumer Protection  
Medical Marijuana Program  
Board of Physicians—Public Hearing  
Minutes  
July 22, 2022

**Members Present:** Michelle Seagull Commissioner  
Dr. Linda Barry  
Dr. Mitchell Prywes  
Dr. Andrew Salner  
Dr. William Zempsky  
Dr. Deepak Cyril D’Souza

**DCP Staff Present:** Rodrick Marriott Director  
Xaviel Soto Program Manager  
Tiffany Araujo Board Administrator

**Call to Order**

Commissioner Seagull called the meeting to order of the Board of Physicians for Connecticut’s Medical Marijuana Program at 8:31 a.m. via Zoom.com

**Review and Approval of Prior Meeting Minutes**

A motion was made by Dr. Salner and seconded by Dr. Prywes and the draft minutes of the October 15, 2021, meeting are accepted.

**Program Update**

- Commissioner Seagull reported that the program has about 51,000 patients and about 1,575 certifying practitioners.
- July 2023 the \$100.00 Medical Marijuana application fee will be removed. Also, the prescription monitoring program is now being updated in real time therefore patients no longer need to submit requests to change their dispensaries.
- Lab testing regulations have been updated with a focus of making sure there is no aspergillus detected.
- Adult use may begin as soon as the end of this year, hybrid retailers for both markets will have pharmacists. In part of conversion, we will be evaluating how they will protect the medical program.
- Delivery is now available; some locations have started already. In connection with adult use there will be some benefits for the medical program such as seed to sale tracking system will improve monitoring product through the supply chain.

### **Presentation by Dr. Sinha on Medical Marijuana Study for Pain and Stress**

Dr. Sinha provided the Board with a presentation on the study of pain and stress. Study 1 covers the evaluation of dosage response curves and subjective physiologic and endocannabinoid response to pain. Study 1 started as inpatient but then changed to include an outpatient option. Also, Study 1 had 6 separate sessions of single dose administration of Placebo, 40 CBD, 100CBD combination of CBD+THC (40/10, 40/20, 100,30). Study 2 will use the best dose from Study 1 which was based on pharmacokinetic and pharmacodynamic. Study 2 focuses on side effects and response to pain and stress. In conclusion, Study 1 doses 40/10 (4:1) and 100/30 (3:1) of CBD/THC were better than the placebo and other doses. It was proven to reduce overall pain, provoked pain, and anxiety. Study 2 has not yet begun, it is still in the preliminary process of getting approvals and patients.

### **Adjournment**

Commissioner Seagull adjourned the meeting at approximately 9:30 a.m.